Find VP level buyers at Agilis Biotherapeutics
Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced that multiple abstracts by its collaborators and partners were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-19, 2018, in Chicago, IL. Agilis’ gene therapy candidate, AGIL-AADC, is an investigational therapeutic adminiAgilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Markus Peters, Ph.D., Agilis Chief Commercial Officer (CCO), will give a presentation on the topic “Evaluating Potential Pricing Strategies for Gene Therapies” and participate in the panel discussion “Pricing, Reimbursement & Market Access Considerations” during tAgilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced that Agilis Chief Medical Officer, Kirsten Gruis, M.D., will present a platform paper entitled “Gene Therapy in Children with AADC Deficiency with AGIL-AADC Leads to De Novo Dopamine Production and Sustained Improvement in Motor Milestones over 5 Years,” at the American AcadAgilis Biotherapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#Agilis--Agilis Biotherapeutics, Inc. (Agilis), a clinical-stage biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Mark Pykett, VMD, PhD, Agilis President and CEO, will speak to the investment community at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will be held on January 9, 2018 at 10:30 am PST. About Agilis Bioth
Read more news
